Pear Therapeutics- Warrants (01/12/2026) OverviewPear Therapeutics- Warrants (01/12/2026)'s EBIT is $-120M, below the sector sector average of $-6.4M.
Get informed when a big investor buys or sells
+ FollowAs of Dec 31, 2022
Trailing 12 months ending Dec 31, 2022
The latest EBIT for PEARW is $-120M as of December 2022. That compares with $-36M in the prior-year period — down 241.4% year over year. That is below the sector sector average of $-6.4M. Investors often review this figure alongside Pear Therapeutics- Warrants (01/12/2026)'s historical trend and sector peers before judging valuation or financial health.
Over the past year, PEARW's EBIT moved from $-36M to $-120M — a 241.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Pear Therapeutics- Warrants (01/12/2026)'s operating scale or balance-sheet position.
Against its sector companies, PEARW currently prints $-120M for EBIT, while the sector average sits near $-6.4M. That is roughly 1826.7% below the sector mean. Large gaps often invite a closer look at Pear Therapeutics- Warrants (01/12/2026)'s growth, margins, and balance sheet.
A EBIT figure of $-120M for PEARW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $-6.4M. Explore the charts below for those layers of context.
After noting PEARW's EBIT ($-120M), review year-over-year change from $-36M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
